Clostrabio

Chicago, US · Delaware corporation · 2 known investors

ClostraBio develops next-generation probiotics and a platform for delivering bacterial metabolites to support gut health, targeting inflammatory bowel disease (IBD) and food allergy. Its lead product, CLB101 (Anaerostipes caccae), is a probiotic aimed at supporting gut barrier function, immunity, and microbiome balance, offered both as a dietary supplement and a therapeutic delivery platform.

BiotechDigital HealthHealthtechin /clostrabio-inc

Founders & leadership

Brett NewswangerChief Operating Officer

Jeffrey HubbellSecretary

Cathryn NaglerPresident

John FlavinExecutive Chairman

Investors · 2

Portal InnovationsChicago

Stone Mountain VenturesDallas · $5Mvia John Diaz · inferred

Competitors · 7

by search overlap

Diabetes Prevention Program14 shared keywords

Nutraingredients7 shared keywords

Labcentral7 shared keywords

KATHERA BIOSCIENCE INC6 shared keywordsKathera Bioscience is a drug discovery company developing broad-spectrum antifungal therapies that target novel fungal enzymes without existing FDA-approved drugs, intended for use as monotherapy or in combination with current antifungal drugs to treat drug-resistant fungal infections. The company operates within the Institute for Life Science Entrepreneurship (ILSE) incubator in Union, New Jersey.

智慧芽 (PatSnap)6 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.

Bridgebio6 shared keywords

Structure Therapeutics5 shared keywords

Companies competing with Clostrabio for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements

▶$9.9MraisedSep 2022 · 15 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Brett NewswangerExecutive Officer
Jeffrey HubbellExecutive Officer, Director
Cathryn NaglerExecutive Officer, Director
John FlavinExecutive Officer, Director

Offering amount: $11M
Amount sold: $9.9M
First sale: Sep 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.